Search

AstraZeneca PLC

Gesloten

SectorGezondheidszorg

11,132 -1.83

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11068

Max

11132

Belangrijke statistieken

By Trading Economics

Inkomsten

1.3B

2.9B

Verkoop

-1.3B

14B

K/W

Sectorgemiddelde

29.321

40.048

Dividendrendement

2.87

Winstmarge

21.46

Werknemers

94,300

EBITDA

648M

5.1B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+20.74% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.87%

2.45%

Volgende dividenddatum

8 sep 2025

Volgende Ex Dividend datum

7 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-15B

167B

Vorige openingsprijs

11133.83

Vorige sluitingsprijs

11132

Nieuwssentiment

By Acuity

64%

36%

327 / 375 Rangschikking in Healthcare

AstraZeneca PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 jul 2025, 08:08 UTC

Winsten

AstraZeneca Books Record Quarterly Revenue as U.S, Oncology Boosts Growth -- Update

29 jul 2025, 06:46 UTC

Winsten

AstraZeneca Books Record Quarterly Revenue as Oncology Boosts Growth

1 aug 2025, 11:10 UTC

Populaire aandelen

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

29 jul 2025, 11:02 UTC

Winsten

AstraZeneca 2Q Adj EPS $2.17 >AZN.LN

29 jul 2025, 11:02 UTC

Winsten

AstraZeneca 2Q EPS $1.58 >AZN.LN

29 jul 2025, 11:01 UTC

Winsten

AstraZeneca 2Q Rev $14.5B >AZN.LN

29 jul 2025, 11:00 UTC

Winsten

AstraZeneca Results: H1 and Q2 2025

29 jul 2025, 08:00 UTC

Marktinformatie
Winsten

AstraZeneca Holding Back on a Guidance Upgrade Disappoints -- Market Talk

29 jul 2025, 07:53 UTC

Marktinformatie
Winsten

AstraZeneca Continues to Deliver Under U.S. Tariff Threat -- Market Talk

29 jul 2025, 07:26 UTC

Marktinformatie
Winsten

AstraZeneca Shares Look Undervalued -- Market Talk

29 jul 2025, 06:03 UTC

Winsten

Analysts Saw AstraZeneca 2Q Total Revenue at $14.15B

29 jul 2025, 06:03 UTC

Winsten

AstraZeneca 2Q Total Revenue $14.46B

29 jul 2025, 06:03 UTC

Winsten

Analysts Saw AstraZeneca 2Q Core EPS at $2.16

29 jul 2025, 06:03 UTC

Winsten

AstraZeneca 2Q Core EPS $2.17

29 jul 2025, 06:02 UTC

Winsten

AstraZeneca Sees Core EPS Increasing by a Low Double-Digit Percentage

29 jul 2025, 06:02 UTC

Winsten

AstraZeneca Sees Total Revenue Increasing by a High Single-Digit Percentage

29 jul 2025, 06:02 UTC

Winsten

AstraZeneca Backs 2025 View

29 jul 2025, 06:00 UTC

Winsten

AstraZeneca PLC 2Q Rev $14.46B

29 jul 2025, 06:00 UTC

Winsten

AstraZeneca PLC 2Q Adj EPS $2.17

29 jul 2025, 06:00 UTC

Winsten

AstraZeneca PLC 2Q Pretax Pft $3.13B

29 jul 2025, 06:00 UTC

Winsten

AstraZeneca PLC 2Q Net Pft $2.45B

29 jul 2025, 06:00 UTC

Winsten

AstraZeneca PLC 2Q Oper Pft $3.51B

29 jul 2025, 06:00 UTC

Winsten

AstraZeneca PLC 2Q EPS $1.57

28 jul 2025, 10:51 UTC

Marktinformatie

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

22 jul 2025, 10:19 UTC

Marktinformatie

AstraZeneca's Big U.S. Spending Plans Could Put NY Listing on the Table -- Market Talk

22 jul 2025, 09:34 UTC

Populaire aandelen

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

9 jul 2025, 10:59 UTC

Marktinformatie

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9 jul 2025, 09:17 UTC

Populaire aandelen

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

28 mei 2025, 18:09 UTC

Winsten

Heart Disease Could Be a Goner When These New -2-

28 mei 2025, 18:09 UTC

Winsten

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

AstraZeneca PLC Prognose

Koersdoel

By TipRanks

20.74% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13,406.92Ā GBXĀ  20.74%

Hoogste 16,500Ā GBX

Laagste 10,900Ā GBX

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor AstraZeneca PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

9

Buy

3

Hold

0

Sell

Sentiment

By Acuity

327 / 375 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.